CRADD抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P08669(CRADD Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

CRADD (CASP2 and RIPK1 domain-containing adaptor with death domain), also known as RAIDD, is a pivotal adaptor protein involved in apoptosis and inflammatory signaling pathways. Structurally, it contains a death domain (DD) and a caspase recruitment domain (CARD), enabling interactions with other DD/CARD-containing proteins like caspase-2 (CASP2) and receptor-interacting protein kinase 1 (RIPK1). CRADD facilitates the activation of CASP2 in the PIDDosome complex (composed of PIDD, CRADD, and CASP2), which regulates apoptosis in response to DNA damage. Additionally, it interacts with RIPK1 to modulate NF-κB signaling and necroptosis under inflammatory conditions.

CRADD antibodies are essential tools for studying these pathways, enabling detection of CRADD expression, localization, and protein interactions via techniques like Western blot, immunoprecipitation, and immunofluorescence. Researchers use these antibodies to explore CRADD's roles in development, homeostasis, and diseases such as neurodegeneration, cancer, and autoimmune disorders. For instance, altered CRADD expression has been linked to Alzheimer’s disease pathology and tumor suppression mechanisms. Validated CRADD antibodies (monoclonal or polyclonal, often raised in rabbits or mice) typically undergo specificity checks using knockout controls. Their applications extend to elucidating cell death mechanisms and identifying therapeutic targets, underscoring CRADD's significance in balancing apoptosis, inflammation, and cell survival.